|
Castle Biosciences Inc (NASDAQ: CSTL) |
|
Castle Biosciences Inc
CSTL's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Castle Biosciences Inc growth rates, revenue grew
by 30.54 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1327
Medical Laboratories industry recorded
growth of revenues by 6.35 %
Castle Biosciences Inc realized net income compared to net loss a year ago in IV. Quarter 2024
• More on CSTL's Growth
|
|
Castle Biosciences Inc current PE on trailing twelve month basis is above Medical Laboratories industry average.
Castle Biosciences Inc PEG ratio is at -0.27
Company is currently trading with Price to Cash flow multiple of 27.99 in trailing twelve-month period. |
Company |
34.09 |
PE TTM
|
Industry |
-0 |
PE TTM
|
|
Company's Price to Sales ratio is at 1.76.
Medical Laboratories industry's Price to Sales ratio is at 2.2.
• More on CSTL's Valuation
|
|
|
|
|
Castle Biosciences Inc current PE on trailing twelve month basis is above Medical Laboratories industry average.
Castle Biosciences Inc PEG ratio is at -0.27
Company is currently trading with Price to Cash flow multiple of 27.99 in trailing twelve-month period. |
Company |
34.09 |
PE TTM
|
Industry |
-0 |
PE TTM
|
|
Company's Price to Sales ratio is at 1.76.
Medical Laboratories industry's Price to Sales ratio is at 2.2.
Castle Biosciences Inc Price to Book Ratio is at 1.28 lower than Industry Avg. of 149.13. and higher than S&P 500 Avg. of 0.01
• More on CSTL's Valuation
|
|
CSTL's Profitability Comparisons
|
Castle Biosciences Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in IV. Quarter 2024 to 4.69 % from 5.92 % in III. Quarter.
Castle Biosciences Inc net profit margin of 14.48 % is currently ranking no. 10 in Medical Laboratories industry, ranking no. 94 in Healthcare sector and number 1086 in S&P 500.
Profitability by Segment |
Total |
12.3 % |
|
|
Castle Biosciences Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in IV. Quarter 2024 to 4.69 % from 5.92 % in III. Quarter.
Castle Biosciences Inc net profit margin of 14.48 % is currently ranking no. 10 in Medical Laboratories industry, ranking no. 94 in Healthcare sector and number 1086 in S&P 500.
• More on CSTL's Key Ratios
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com